Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.
9360 TOWNE CENTRE DR SUITE 110 SAN DIEGO, CA 92121, USA Phone: 6195522200 Fax: 858-552-2212 Web: http://www.amylin.com Email: IR@amylin.com
Industry:MED-BIOMED/GENE Sector: Medical Fiscal Year End:December Last Reported Quarter:12/31/11 Next EPS Date:04/16/12
Capital Structure Solvency and Cash Flow
Capital Structure
As of March 31, 2010, the company held cash, cash equivalents and short-term investments of $598.3 million versus $667.8 million as of December 31, 2009. Management expects to generate a steady positive operating cash flow by the end of 2010, as well as a positive non-GAAP operating income for 2011 and a GAAP operating profit by the end of 2011.
For FY10, the management continues to expect capital expenditure (net of reimbursements from Eli Lilly) of less than the $98 million recorded in 2009, which will support Exenatide life cycle management. Furthermore, management intends to repay the current $86 million in outstanding debt.
Last edited Fri May 14, 2010 03:05 AM by SudiptaMukherjee (Zacks Investment Research)
Governance Social Responsibility and Employee Relations
Though the company generates considerable gross profits from the sale of Byetta and Symlin, it is in a cash-burn mode due to its significant R&D and SG&A investments.
DPP-IV inhibitors may offer many of the benefits of Byetta in pill form. Other GLP-1 analogs in development offer a more convenient dosing regimen and represent a significant competitive threat.
The timely approval of Exenatide LAR remains a concern based on both pancreatitis and thyroid cancer risk.
Last edited Fri May 14, 2010 03:07 AM by SudiptaMukherjee (Zacks Investment Research)
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 06:15:37 CDT by WikiMigrationBot.
